RANI

Rani Therapeutics Holdings Inc

RANI, USA

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

https://www.ranitherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RANI
stock
RANI

Dip Buying: Will RANI stock return to pre crisis levels - Earnings Summary Report & Scalable Portfolio Growth Methods moha.gov.vn

Read more →
RANI
stock
RANI

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$9.25

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-6.35

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

68.85 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-53.38 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 14.38% of the total shares of Rani Therapeutics Holdings Inc

1.

Armistice Capital, LLC

(6.5793%)

since

2025/06/30

2.

Vanguard Group Inc

(1.6695%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(1.0598%)

since

2025/07/31

4.

United Services Automobile Association

(0.6321%)

since

2025/06/30

5.

Takeda Pharmaceutical Co Ltd

(0.4242%)

since

2025/06/30

6.

Geode Capital Management, LLC

(0.3978%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.377%)

since

2025/07/31

8.

KESTRA PRIVATE WEALTH SERVICES, LLC

(0.326%)

since

2025/06/30

9.

Citadel Advisors Llc

(0.2868%)

since

2025/06/30

10.

BlackRock Inc

(0.2477%)

since

2025/06/30

11.

Northern Trust Corp

(0.2149%)

since

2025/06/30

12.

Fidelity Extended Market Index

(0.2016%)

since

2025/07/31

13.

CWA Asset Management Group, LLC

(0.174%)

since

2025/06/30

14.

Lasry Marc

(0.1313%)

since

2025/06/30

15.

State Street Corp

(0.1304%)

since

2025/06/30

16.

UBS Group AG

(0.1296%)

since

2025/06/30

17.

King Luther Capital Management Corp

(0.1211%)

since

2025/06/30

18.

Janney Montgomery Scott LLC

(0.1152%)

since

2025/06/30

19.

Well Done, LLC

(0.1086%)

since

2025/06/30

20.

iShares Micro-Cap ETF

(0.1047%)

since

2025/08/31

21.

Motco

(0.1005%)

since

2025/06/30

22.

Insigneo Advisory Services LLC

(0.0992%)

since

2025/06/30

23.

Bridgeway Capital Management, LLC

(0.0971%)

since

2025/06/30

24.

Bridgeway Ultra-Small Company Market

(0.0971%)

since

2025/06/30

25.

Brown Advisory Holdings Inc

(0.0687%)

since

2025/06/30

26.

Fidelity Series Total Market Index

(0.056%)

since

2025/07/31

27.

Fidelity Total Market Index

(0.0545%)

since

2025/07/31

28.

Spartan Extended Market Index Pool F

(0.0507%)

since

2025/07/31

29.

Northern Small Cap Core I

(0.0462%)

since

2025/06/30

30.

Northern Trust Extended Eq Market Idx

(0.0339%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - L

(0.0339%)

since

2025/06/30

32.

Extended Equity Market Fund K

(0.0332%)

since

2025/06/30

33.

NT Ext Equity Mkt Idx Fd - NL

(0.0303%)

since

2025/06/30

34.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0297%)

since

2024/12/31

35.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0235%)

since

2025/06/30

36.

NT Quality Small Cap Core

(0.0226%)

since

2025/06/30

37.

NT Quality SCC US Fund - L

(0.0226%)

since

2025/06/30

38.

Spartan Total Market Index Pool G

(0.0199%)

since

2025/07/31

39.

Fidelity Nasdaq Composite Index

(0.015%)

since

2025/07/31

40.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0096%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

-0.1667

EPS Difference

0.0467

Surprise Percent

28.0144%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.